BCLI stock icon

Brainstorm Cell Therapeutics
BCLI

$0.39
3.93%

Market Cap: 31.3M

 

About: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Employees: 29

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

6,500% more call options, than puts

Call options by funds: $66K | Put options by funds: $1K

111% more capital invested

Capital invested by funds: $1.04M [Q4 2023] → $2.19M (+$1.15M) [Q1 2024]

0.17% more ownership

Funds ownership: 8.08% [Q4 2023] → 8.25% (+0.17%) [Q1 2024]

0% more funds holding

Funds holding: 46 [Q4 2023] → 46 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$2
409%
upside
Avg. target
$2
409%
upside
High target
$2
409%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Maxim Group
Jason McCarthy
409%upside
$2
Buy
Upgraded
11 Jul 2024

Financial journalist opinion

Based on 5 articles about BCLI published over the past 30 days